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Abstract
Background: Haematotoxicity of conventional chemotherapies often results in delays
of treatment or reduction of chemotherapy dose. To ameliorate these side-effects,
patients are routinely treated with blood transfusions or haematopoietic growth
factors such as erythropoietin (EPO) or granulocyte colony-stimulating factor (G-CSF).
For the latter ones, pharmaceutical derivatives are available, which differ in absorption
kinetics, pharmacokinetic and -dynamic properties. Due to the complex interaction of
cytotoxic effects of chemotherapy and the stimulating effects of different growth factor
derivatives, optimal treatment is a non-trivial task. In the past, we developed
mathematical models of thrombopoiesis, granulopoiesis and erythropoiesis under
chemotherapy and growth-factor applications which can be used to perform clinically
relevant predictions regarding the feasibility of chemotherapy schedules and
cytopenia prophylaxis with haematopoietic growth factors. However, interactions of
lineages and growth-factors were ignored so far.
Results: To close this gap, we constructed a hybrid model of human granulopoiesis
and erythropoiesis under conventional chemotherapy, G-CSF and EPO applications.
This was achieved by combining our single lineage models of human erythropoiesis
and granulopoiesis with a common stem cell model. G-CSF effects on erythropoiesis
were also implemented. Pharmacodynamic models are based on ordinary differential
equations describing proliferation and maturation of haematopoietic cells. The system
is regulated by feedback loops partly mediated by endogenous and exogenous EPO
and G-CSF. Chemotherapy is modelled by depletion of cells. Unknown model
parameters were determined by fitting the model predictions to time series data of
blood counts and cytokine profiles. Data were extracted from literature or received
from cooperating clinical study groups. Our model explains dynamics of mature blood
cells and cytokines after growth-factor applications in healthy volunteers. Moreover, we
modelled 15 different chemotherapeutic drugs by estimating their bone marrow
toxicity. Taking into account different growth-factor schedules, this adds up to 33
different chemotherapy regimens explained by the model.
Conclusions: We conclude that we established a comprehensive biomathematical
model to explain the dynamics of granulopoiesis and erythropoiesis under combined
chemotherapy, G-CSF, and EPO applications. We demonstrate how it can be used to
make predictions regarding haematotoxicity of yet untested chemotherapy and
growth-factor schedules.
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Background
Haematotoxicity of conventional multidrug, multi-cycle chemotherapies often results
in delays of treatment or reduction of chemotherapy dose [1]. To ameliorate these
side-effects, patients are routinely treated with blood transfusions (erythrocyte, platelet
concentrates) or haematopoietic growth factors. For the latter ones, highly potential
pharmaceutical derivatives are available, which however differ in their pharmacokinetic
and -dynamic (PK/PD) properties. Due to the complex interaction of cytotoxic effects of
chemotherapy and the stimulating effects of different growth factors, optimal treatment
is a non-trivial task.
In the past, we developed mathematical models of thrombopoiesis (formation of
platelets responsible for coagulation), granulopoiesis (formation of neutrophil granulo-
cytes responsible for unspecific immune defense) and erythropoiesis (formation of red
blood cells responsible for oxygen supply) under chemotherapy and growth-factor appli-
cations which can be used to perform clinically relevant predictions regarding feasibility
of chemotherapy schedules and cytopenia prophylaxis with haematopoietic growth fac-
tors [2-4]. A few predictions were tested and validated in subsequent clinical trials,
resulting in improved granulocyte colony-stimulating factor (G-CSF) schedules [5,6].
However, interactions of lineages and growth-factors were ignored so far.
In this paper, we aim to combine our models of erythropoiesis and granulopoiesis by
constructing a model of both cell lines under chemotherapy, G-CSF and erythropoi-
etin (EPO) applications. Rather than constructing a model from scratch we rely on the
above mentioned established models to perform a second step towards a more com-
prehensive model. This implies that we kept the major model assumptions, equations
and parameters of the isolated erythropoiesis and granulopoiesis model as far as
possible.
Our goal is to create a hybrid model of human granulopoiesis and erythropoiesis
usable for simulations of various chemotherapy schedules with EPO and G-CSF
support taking into account interactions of the lineages via G-CSF effects on ery-
thropoiesis [7-9]. Combining the models at stem cell level is a challenging issue,
since the regulation of the stem cell compartment differs between the single lineage
models.
In the present paper, we describe adaptations necessary to combine themodels in detail.
We compare the new hybrid model with the single lineage models for a number of sce-
narios such as cell loss or single injections of growth-factors. We also validate the hybrid
model on the basis of a large number of data sets obtained from phase I, II and III clin-
ical trials containing growth-factor or chemotherapy applications or combinations of it.
Finally, we perform predictions regarding combined EPO and G-CSF applications during
chemotherapy.
Methods
General structure of the model
We aim at constructing a hybrid model of human erythropoiesis and granulopoiesis
under chemotherapy, G-CSF and EPO applications by combining an ordinary differential
equations model of erythropoiesis [10] and granulopoiesis [3] established recently. The
single lineage models have a similar structure: Both consist of a number of concatenated
cell compartments representing different proliferating and maturing cell stages in bone
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marrow and circulation (see Figure 1). Dynamics of cell compartements are described by
balance equations of the general form:
d
dtC = A
in · Cin − CT (1)
where Ain is the amplification of the influx derived from the overall amplification A (see
Additional file 1 section A.1 for details). T is the transition time, Cin is the efflux rate
from the preceding cell compartment, and C the content of the cell compartment (see
[3,4,10-14]).
The quantities A and T are usually regulated by growth factors, namely EPO for
the erythropoiesis model and G-CSF for the granulopoiesis model. Concentrations of
these growth-factors as well as external applications are also explicitely modelled. The
quantities A and T are regulated between a minimum and a maximum according to the






Figure 1 Structure of the model of erythropoiesis and granulopoiesis under chemotherapy, G-CSF
and EPO application.Model compartments are presented in boxes (S = stem cells, BE = burst forming
units - erythroid, CE = colony forming units - erythroid, PEB = proliferating erythrocytic blasts, MEB =
maturing erythrocytic blasts, RET = reticulocytes, ERY = erythrocytes, EPO = erythropoietin, CG =
granulopoietic progenitor cells (colony forming units of granulocytes and macrophages), PGB = proliferating
granulopoietic precursor cells (myeloblasts, promyelocytes, myelocytes), MGB = maturing granulopoietic
precursor cells (metamyelocytes, banded and segmented granulocytes)), GRA = granulocytes, LY =
lymphocytes, CX = chemotherapy. Several regulatory feedback loops are displayed. The most important two
are mediated by EPO and by G-CSF which are produced endogenously and could also be applied externally.
Chemotherapy is modelled by a transient depletion of cells.














for Ymin < Ynor < Ymax or Ymax < Ynor < Ymin
Ynor for Ymin < Ynor < Ymax,
(3)





centration of either EPO or G-CSF and bY is the sensitivity of Y under stimulation. Ymin
and Ymax are minimum and maximum values of Y respectively. The function 3 is called
regulatory function in the following (see also [12], p. 69).
Amplification and maturation time may depend on the concentration of the growth
factors G-CSF and EPO, denoted as CrelGCSF(t) for the G-CSF concentration in the central
compartment, or CintEPO(t) for the EPO internalised by red blood cells respectively. Details
of growth factor mediated regulations as well as assumptions regarding pharmacokinetics
and -dynamics of growth-factors are explained in sections ‘Erythropoiesis model’ and
‘Granulopoiesis model’.
Both single lineage models contain similar but not identical models of stem cell dynam-
ics which have a different structure than Equation 1. Since the stem cell compartment
is crucial for combining the models, we explain it in more detail in section ‘Stem cell
compartment S’. Finally, a model of chemotherapy effects was introduced to the lineage
models which is explained in section ‘Chemotherapy model’. A complete set of all model
equations can be found in the Additional file 1.
Erythropoiesis model
The cell kinetic model of erythropoiesis is adopted from earlier modelling works of
our group with respect to erythropoiesis in mice and humans [10-13,15,16]. This part
of the model describes the development of mature erythrocytes from haematopoietic
stem cells and its regulation by endogenous EPO. It consists of the cell compartments
S (stem cells), BE (burst forming units - erythroid), CE (colony forming units - ery-
throid), PEB (proliferating erythrocytic blasts), MEB (maturing erythrocytic blasts), RET
(reticulocytes), ERY (erythrocytes), and EPO concentrations of different sites (see also
Figure 1).
EPO is assumed to increase the proliferation and to shorten the maturation time of red





is assumed to depend on the oxygen partial pressure in the kidneys and the number of cir-
culating red blood cells [11,13]. A detailed description of the model of EPO applications
can be found in [10]. In brief, it consists of a pharmacokinetic model of EPO (adapted
from [17]) and a subcutaneous injection model of EPO (adapted from [18]). The PK













[17], with first order transitions
between the peripheral and the central compartment describing reversible protein bind-
ing of EPO. EPO can bind to free EPO receptors forming a drug-receptor complex which
dissociates again or EPO is internalised. EPO is removed from circulation by the latter
mechanism or via unspecific elimination modelled by a first order loss term. Internalised
EPO serves as argument of all regulation functions regarding EPO.
Different pharmaceutical EPO derivatives are modelled: EPO Alfa, EPO Beta, EPO
Delta and Darbepoetin Alfa. The first three are recombinant human EPO derivatives of
Schirm et al. Theoretical Biology andMedical Modelling 2014, 11:24 Page 5 of 28
http://www.tbiomed.com/content/11/1/24
the first generation differing only in their glycosylation patterns. Darbepoetin Alfa is a
next generation EPO pharmaceutical with increased half-life in serum.
Different application sites of EPO result in different absorption kinetics [18]. While
intravenous injections can simply be modelled by pulse functions, subcutaneous injec-
tions are characterised by delayed and incomplete absorption resulting in a reduced
bioavailability [19-21]. To account for this fact, we adapted a model of subcutaneous EPO
injection developed for sheep [18]. The model contains two absorption routes: directly
from the subcutaneous tissue into the bloodstream, or indirectly via the lymphatic sys-
tem. In both processes, we included time delays by concatenated sub-compartments with
first order transitions (see Additional file 1, section A.3 for details). A loss of EPO is
assumed at the injection site and in the lymphatic system. The structure of this injec-
tion model is described in detail in [10,18]. All equations can be found in the Additional
file 1.
Due to differences in the lymphatic flow at different anatomical regions [18,19,22], we
split available injection modi into different groups. While the parameters describing sub-
cutaneuos injection can differ between these groups, the PK parameters are the same for
endogenous EPO and all EPO derivatives except for Darbepoetin. Available data allowed
to specify parameter settings for injections of EPO Alfa into thigh, EPO Alfa into shoul-
der, EPOAlfa into forearm, EPOAlfa into upper arm or abdomen, EPOBeta into forearm,
EPO Beta into arm or abdomen, EPO Beta into thigh, EPODelta, and finally, Darbepoetin
Alfa (see [10]).
A model of chemotherapy action on erythropoiesis is added as explained in
section ‘Chemotherapy model’.
Granulopoiesis model
The cell kinetic model of granulopoiesis also constructed by our group [3,4,12,23]
describes the development of mature granulocytes from haematopoietic stem cells and
its regulation by G-CSF. It consists of the cell compartments S (stem cells), the granu-
lopoietic progenitors CG (colony forming units of granulocytes and macrophages), the
proliferating granulopoietic precursors PGB (myeloblasts, promyelocytes, myelocytes),
the maturing granulopoietic precursors MGB (metamyelocytes, banded and segmented
granulocytes), the granulocytes GRA andG-CSF concentrations at different sites (see also
Figure 1).
We consider both, endogenously produced G-CSF and injections of the derivatives Fil-
grastim and Pegfilgrastim. Endogenous G-CSF production is regulated by the demand of
mature granulocytes. In analogy to former versions of our model [3,4], this is modelled
phenomenologically as a function of the content of the final bone marrow compartment
and circulating granulocytes.
Pharmacokinetics of endogenous G-CSF and injections are modelled by three com-
partments: a subcutaneous compartment CscG-CSF in which G-CSF pharmaceuticals are
injected, a central compartment CcentG-CSF in which the drugs are pharmacologically active
and a peripheral compartment CperiG-CSF representing reversible protein binding [24]. This
model was originally developed for mice and rats and later adopted for the human
situation [3,25,26].
Exogenous G-CSF applications are modelled by an injection function analogous to EPO
injections. Delayed influx of injected G-CSF from the subcutaneous compartment into
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the central compartment caused, e.g., by lymphatic absorption [18] is modelled by divi-
sion of the subcutaneous compartment into two subcompartments (for details regarding
modelling of delays see Additional file 1 section A.3). Dose-dependent bioavailability of
G-CSF [26] is modelled by aMichaelis-Menten loss termwithin the first subcompartment
of the subcutaneous tissue [3]. Transitions between central and peripheral compartments
were modelled by two-way first order kinetics [27].
G-CSF is eliminated from the central compartment via two routes: Unspecific renal
elimination of G-CSF is modelled by a first order kinetic [27,28]. Specific degradation
mediated by the number of circulating granulocytes is modelled by a Michaelis-Menten
kinetic proportional to this number [3,25,29-32].
We use the same pharmacokinetic and -dynamic parameter settings for Filgras-
tim and endogenous G-CSF because of their high similarity [33-35]. The observed
differences between Filgrastim and Pegfilgrastim [4,28,36-40] are modelled using the
same model structure but different parameters settings for absorption, distribution,
degradation and regulatory mechanisms (regulatory functions). Receptor competi-
tions between Pegfilgrastim and endogenous G-CSF (or Filgrastim) is modelled by
adding the regulatory functions of Pegfilgrastim and Filgrastim using a weighting
factor.
Pharmacokinetic and -dynamic modelling of G-CSF is described in detail in [3,4]. In
our former model, we assumed a delayed effect of G-CSF on bonemarrow cells. Since this
effect was rather small, we decided to drop it in the combined model in order to reduce
complexity and computational burden.
A model of chemotherapy is attached to our granulopoiesis model as explained in
section ‘Chemotherapy model’.
Stem cell compartment S
Cells differentiating into granulopoietic or erythropoietic lineages originate from a com-
mon pool of cells called haematopoietic stem cells ([41]). We used the same equations
of stem cell dynamics in our models of granulopoiesis and erythropoiesis, but regula-
tions were slightly different. Basic concepts can be traced back to the book of Loeffler &
Wichmann [12]. Since the stem cell compartment is crucial for combining the models we
present its structure in more detail now.
The stem cell compartment has self-renewal capability. To achieve a steady state, on
average 50% of the proliferating stem cells remain in this compartment, and 50% differen-
tiate into red or white blood cell lineages. Hence, the compartment equation differs from
Equation 1:
d








where τS is the average duration of a cell cycle, p the self-renewal probability, aS is the
proliferative fraction, CS is the size of the stem cell compartment and CoutS its efflux com-
mitting to the haematopoietic lineages. According to [12], the self-renewal probability p
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is regulated by the demand of the hematopoietic bone marrow system. In steady state, we
assume pnor = 12 . Thus, for the initial conditions (steady state) it holds that
CS(0) = CnorS = 1 (6)
CoutS (0) = Cout_norS = 2
(
1 − pnor)CnorS anorSτS . (7)
Similar to the stem cell model of [12], self-renewal of stem cells p is regulated by a
















CrelS (t),CrelE (t),CrelG (t), pδ ,ϑE,ϑG,ϑS(t)
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The parameters ϑE,ϑG, and ϑS are hypothetical weighting factors originally defined




CnorBE +CnorCE +CnorPEB+CnorBE , and C
rel
G (t) = CCG(t)+CPGB(t)+CMGBCnorCG+CnorPGB+CnorMGB .
According to [12], it is assumed that
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2 for CrelS (t) > 1
















where pnor = 12 , ϑG = −8, ϑE = −2.
In our single lineage models, this regulation was simplified in different ways. Since ery-
thropoiesis was not included in the model of granulopoiesis, only granulopoietic cells CrelG
were assumed to influence the self-renewal probability in S with the factor ϑG = −10, i.e.
we assumed CrelE = CrelG and thus








CrelG (t) − 1
))
+ 0.5.
In contrast, a constant granulocyte value CrelG = 1 was assumed in our erythropoiesis
model. The erythropoietic bone marrow cells CrelE were multiplied by ϑE = −2, thus








CrelE (t) − 1
))
+ 0.5.
The proliferative fraction aS can be interpreted as the percentage of cells which are
currently in cell cycle. The proliferative fractions aX of the compartments S, BE or CG are
also regulated by the haematopoietic bone marrow system CrelS (t) and CrelG (t) or CrelE (t):
aX = aX
(
CrelS (t),CrelE (t),CrelG (t), aminX , anorX , aintX , amaxX ,ωE,ωG,ωS
)
,
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Again, the parameters ωS,ωG, and ωE are weighting factors. They represent the strengths
of the influence of stem cells, erythropoietic and granulopoietic cells on the proliferative
fraction of BE, CG and S respectively. With
x = ωE lnCrelE (t) + ωG lnCrelG (t) (9)
+ ωS
{
lnCrelS (t), for CrelS ≤ 1
CrelS (t) − 1, for CrelS > 1



















the proliferative fraction is given by
aX =
{ amaxX e−y+aminX ey
e−y+ey for a
min
X < anorX < aintX < amaxX
anorX for aminX = anorX = aintX = amaxX
. (10)
It is a monotone function ranging between aminX and amaxX . Low cell numbers in the
bone marrow compartments cause a higher demand of proliferating cells, and therefore,
a larger proliferative fraction aX . The value of y defines the actual point on the regulatory
curve. The variable x is a measure of the total bone marrow content. It is calculated as a
weighted sum of the logarithms of the relative counts of stem cells, erythropoietic cells
and granulopoietic cells. If any cell counts tend to zero, x tends to minus infinity, and
with it, a becomes maximal. Parameter values aint corresponds to x = − ln 2 and anor
corresponds to x = 0 (see Figure S2 in the Additional file 1).
In analogy to the regulation of the self-renewal probability, a factor ωG = 0.4 is
assumed for the influence of the granulopoietic bone marrow compartments CrelG in the
granulopoiesis model, thus
x = ωG lnCrelG (t) + ωS
{
lnCrelS (t), for CrelS ≤ 1
CrelS (t) − 1, for CrelS > 1
}
.
In contrast, in the erythropoiesis model we assumed a constant granulocyte value
CrelG = 1 and the logarithmized erythropoietic bone marrow cells CrelE are multiplied by
ωE = 0.3, i.e.
x = ωE lnCrelE (t) + ωS
{
lnCrelS (t), for CrelS ≤ 1




We used the same model of chemotherapy in both the erythropoiesis and the granu-
lopoiesis model. It is based on the following assumptions which are extensively discussed
in [2-4]: Chemotherapy results in a delayed, reversible and transient depletion of the
compartments S, CG, PGB, MGB, BE, CE, PEB, MEB, and RET, where the toxic effect
is specific for the cell stages, for different drugs or drug combinations, and for different
doses of the same drug. This is quantified by corresponding sets of toxicity parameters
(see tables A.8 and A.9 in the Additional file 1). A higher toxicity in the first chemotherapy
cycle is modelled by a factor f drugfc ≥ 1. It is assumed that different cytotoxic drugs damage
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independently of each other. This allows us to add toxicity functions of chemotherapeutic
drugs applied in combinations.
Infusion of chemotherapeutic drugs is again modelled using pulse functions. The effect
of chemotherapy is introduced to the balance equations of the bone marrow cell com-
partments by a first-order loss term X . Hence, the modified schematic compartment
Equation 1 has the form
d
dtCX = A
in · CinX −
CX
T − X · CX (11)
for X ∈ {CG, PGB, MGB, BE, CE, PEB, MEB, RET}. X depends on the kind, dose and
timing schedule of chemotherapy as well as on the affected bone marrow comparted X
(see Additional file 1 for further details). Analogously, the modified stem cell Equation 4
has the form
d
dtCS = (2p − 1)CS
aS
τS
− S · CS. (12)
In clinical practice often only leukocytes, i.e. the sum of unspecific (granulocytes)
and specific (lymphocytes) immune cells, are available. To avoid additional modelling of
lymphopoiesis, the reduced lymphocyte count under chemotherapy is described by an
exponential function of the form (see [3]):
CWBC (t) ≈ cLY exp (−LY (t)) + cGRACGRA (t)CnorGRA
,
where cLY = 3000 cells per μl and cGRA = 4000 cells per μl are the steady state con-
centrations of lymphocytes and granulocytes respectively. LY is the toxicity function for
lymphocytes which is analogously defined as the toxicity functions of bone marrow cell
stages.
Age is a major risk factor of haematotoxicity under chemotherapy [1]. In our for-
mer granulopoiesis model [4], we assumed different toxicity parameters for the age
groups ≥60 years and <60 years. This assumption will be carried over to our hybrid
model.
Combination of granulopoiesis and erythropoiesis models
It is our major intention to keep the single lineage models as unchanged as possible. But
a few assumptions are necessary to combine them. These assumptions refer to the reg-
ulation of stem cells, the interaction of granulopoiesis and erythropoiesis, and common
chemotherapy effects.
In the following, we describe the assumptions and necessary modifications of the single
lineage models in detail. A schematic representation comprising all parts of the model is
shown in Figure 1.
Common stem cell compartment
In the single lineage models, the concurrent influence of erythropoietic and myeloid
cells on the regulation of the stem cell compartment, i.e. the regulation of self-renewal
probability and proliferative fraction, could not be considered. This resulted in a num-
ber of simplifications explained in section ‘Stem cell compartment S’. When combining
the single lineage models, these simplifications are no longer required. Hence, we rely
on the extended regulatory functions regarding proliferative fraction and self-renewal
(Equations 8, 9 and 10). The same regulatory principles were used for the proliferative
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fractions of the compartments BE and CG, i.e. these quantities now also depend on both,
relative stem cell count (CrelS ), relative size of bone marrow erythropoiesis (CrelE ) and
granulopoiesis (CrelG ).
Furthermore, we implemented a splitting of the output of the stem cell compartment
which feeds both lineages.We assume that 15% of the released cells (CoutS , see Equation 7),
differentiate into red blood cells (αE = 0.15), and 80% into the white blood cell line
(αG = 0.8, see also [12], pp. 61, 62). However, these parameters are dummies having no
impact on the behaviour of the model in its current form since only relative changes of
compartment sizes are considered. They will become relevant later when implementing a
model of lineage commitment [42]. Hence, the influx into the subsequent erythropoietic
and granulopoietic progenitor compartments reads as follows:
CinBE = 0.15CoutS
CinCG = 0.8CoutS
Note that 5% of stem cells are assumed to commit to thrombopoietic lineage.
Compartment CE and G-CSF effect on erythropoiesis
In our single lineage model of erythropoiesis, the amplification and transition time in
compartment CE is only regulated by the growth factor EPO. Nowwe additionally assume
an inhibiting influence of endogenous G-CSF, Filgrastim and Pegfilgrastim on this com-
partment. Evidence for interactions of Erythropoietin and G-CSF and mutual influence
of the different lineages is described in [7,8,43].
This interaction is modelled by additional regulatory functions of G-CSF multiplied to
those of amplification and transition time of the compartment CE (see Equation 3 and








) · FT_GCSF(t). (14)
with
FA_GCSF(t) = wP(t) · ZA_Peg(t) + (1 − wP(t)) · ZA_Fil(t) (15)
FT_GCSF(t) = wP(t) · ZT_Peg(t) + (1 − wP(t)) · ZT_Fil(t) (16)
where ZACE , ZTCE are the regulatory functions of amplification and transition time in
compartment CE, ZT_Fil(t), ZA_Fil(t) and ZA_Peg(t), ZT_Peg(t), are regulatory functions of
endogenous G-CSF respectively of Filgrastim and Pegfilgrastim, 0 ≤ wP(t) ≤ 1 is the
weighting factor to model the superimposing effect of concurrent endogenous G-CSF /
Filgrastim and Pegfilgrastim action (see [3]), and CintEPO is the internalised EPO (see [10]).
The fitting process performed later resulted in a rather small influence of Filgrastim and
Pegfilgrastim on the amplification in CE. Therefore, we decided to set FA_GCSF(t) = 1. A
complete set of parameters regarding this regulation is listed in Table 1.
Common chemotherapymodel
The same chemotherapy model was used in our single lineage models of granulopoiesis
and erythropoiesis. However, combination of the models required some adjustments of
toxicity parameters due to the interactions of the lineages not considered in the previous
models.
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Figure 2 Regulatory functions in compartment CE. Regulatory functions describing the effect of Filgrastim,
Pegfilgrastim, EPO and combinations of it on amplification rate and transition time in the compartment CE.
While amplification is assumed to be unaffected by G-CSF, the transition time is delayed under G-CSF
stimulation. A: Delay factor of transition time - dependence on endogenous G-CSF/Filgrastim concentration.
We mark the values achieved at steady-state (green) and at maximum after a single s.c. application of 480 μg
(black). B: Delay factor of transition time - dependence on Pegfilgrastim concentration. Values achieved at
maximum after a single s.c. application of 6000 μg (black) and steady state (green) are marked. C:
Amplification in CE - dependence on internalised EPO. No G-CSF effects are assumed here.D: Transition times
in CE - dependence on internalised EPO and G-CSF concentration. We present the raw regulatory functions
without considering G-CSF effects (dotted) and maximal deviations after either Filgrastim application of 480
μg (solid) or Pegfilgrastim application of 6000μg (grey). Note that the regulatory functions presented in A and
B are superimposed (Equation 16) under Pegfilgrastim or combined Pegfilgrastim/Filgrastim applications .
Numerical methods for simulation
Simulations were performed with MATLAB 7.5.0.342 (R2007b) using the SIMULINK
toolbox (The MathWorks Inc., Natick, MA, USA). Numerical solutions of the equation
system are obtained using the variable step solver from Adams and Bashford (ode113,
SIMULINK toolbox).
Data sets
We combined the data sets used to establish the single lineage models of erythropoiesis
and granulopoiesis. These data sets comprise time courses of absolute neutrophil counts
Table 1 Parameters for modelling G-CSF effects on compartment CE
Parameter Meaning Filgrastim Pegfilgrastim
TminCEF , T
min
CEP Factor of transition time under minimal stimulation 0.9995 Fitted 1 Set
TnorCEF , T
nor
CEP Factor of transition time under normal stimulation 1 Set 1.037 Fitted
TmaxCEF , T
max
CEP Factor of transition time under maximal stimulation 98.37 Fitted 2.787 Fitted
TbCEF , T
b
CEP Sensitivity of factor of transition time 0.930 Fitted 0.5660 Fitted
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(ANC), white blood cell counts (WBC), hemoglobin (HB), hematocrit (HCT), serum
concentration of EPO and G-CSF, red blood cell counts (RBC), reticulocyte counts (RET),
or percentages of reticulocytes after EPO or G-CSF application in healthy volunteers and
time series data of hemoglobin, ANC orWBC in patients treated with chemotherapy with
or without G-CSF or EPO support. Data sets without access to raw data were taken from
literature. The automated tool “ycasd” [44] was used to extract the data as precisely as
possible. However, in literature often only data of one blood cell lineage per scenario were
available.
We also have access to raw patients data of the German High Grade Non-Hodgkin’s-
Lymphoma Study Group [45-48] and the German Hodgkin’s Lymphoma Study Group
[49,50], and the German Breast Group [51]. These data comprise both, haemoglobin and
leukocyte data for 11 different chemotherapeutic drug combinations. Considering dif-
ferent growth factor schedules, we analysed raw data of 15 different therapy scenarios.
Patients HB data were censored after receiving erythrocyte concentrates. For some ther-
apy schedules we split the data taking into account individual risk groups (young vs.
elderly patients). Combined with the literature data, we modelled 15 different chemother-
apeutic drugs or drug combinations. Taking into account differences in growth factor
schedules results in a total of 33 different therapy schemes. An overview of all data sets
used for modelling is presented in table A.10 in the Additional file 1.
Scenarios were either used to determine unknown parameters of the model or to
validate model predictions.
Estimation of parameters
It is our goal to keep the parameters of our single lineagemodels constant as far as possible
to reduce the problem of over-fitting, but a few adaptations were necessary due to the
changes required for model combination (see section ‘Combination of granulopoiesis and
erythropoiesis models’). While the parameters of the cell kinetic models of granulopoiesis
and erythropoiesis and the pharmacokinetics of EPO and G-CSF described in [3,4] and
[10] were kept constant, we modified chemotherapy parameters and those involved in
regulating amplification and transition time in the modified compartment CE (see tables
of chemotherapy parameters in the Additional file 1 and Table 1).
To estimate toxicity parameters, data of at least one scenario are required in which the
corresponding drug or drug combination was used. Hence, chemotherapy parameters
were established using the EC-T and E-T-C scenarios with G-CSF and with or without
EPO [51], CHOP 21 and CHOEP 21 for young and elderly patients [45,46], the BEACOPP
21 and BEACOPP 21 escalated data [49,50], the high CHOEP 21 data [47], the literature
data with ESHAP and 12× 5 μg/kg Filgrastim or 100 μg/kg Pegfilgrastim on day 6 [52]
and the literature data with Platinum and Etoposide with and without Darbepoetin [53].
Toxicity parameters for the literature scenarios without HB data (Doxorubicin-Docetaxel
[54-57] or Carboplatin-Paclitaxel [58]) were taken from the granulopoiesis model. Due
to lack of data, toxicity parameters for erythropoiesis could not be established for these
scenarios.
Parameters regarding Filgrastim effects on the compartment CE were determinated
using the HB- and WBC-data of the NHL-B trial (CHOP 14, elderly patients, Filgrastim
480 μg day 4–13), the data of E-T-C with EPO and G-CSF on day 3–10, and the data of
the “Ricover” trial (elderly patients, CHOP 14, G-CSF Filgrastim 480 μg day 6–12), since
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these scenarios have simple chemotherapy regimens but different G-CSF schedules infor-
mative for our purposes. Parameters regarding Pegfilgrastim effects on the compartment
CE were determinated on the basis of the data of CHOP 14 with Pegfilgrastim on day 2
and day 4 [5].
For parameter fitting, (1+3)-evolutionary-strategies with self-adapting mutation step
size [59,60] were used. This refers to a non-deterministic optimisation algorithm with
one possibly immortal parent and three children per generation. We applied the fitness
function described in [3,10] based on the area between simulation and data curve:
∫ t1
t0
∣∣log(fmodel(t, k)) − log(fdata(t))∣∣ dt → mink . (17)
fmodel(t, k) is the simulation result at time t for the parameter set k = k1, . . . kn. t0 ≤
t ≤ t1 describe the range of time points for which data are available, and fdata(t) is the
interpolated curve of data medians. Since we model relative sizes of cell compartments,
model outputs are multiplied by normal values to allow comparisons with clinical data.
The fitness value is defined as the left hand side of Equation 17. It is specific for the clin-
ical intervention (e.g. application of a certain chemotherapy), the outcome measure (e.g.
granulocyte counts) and the clinical data set (e.g. median of patient data at certain time
points) considered. Fitness values of different outcomes of the same clinical intervention
are added to calculate an overall fitness value of the scenario. For simultaneous fitting of
more than one scenario, we add corresponding fitness values.
We performed a sensitivity analysis of newly introduced cell kinetic parameters of
our model by changing their values by 2.5% and calculating corresponding deteriora-
tions of the fitness function. It revealed that minimum and normal values of the G-CSF
regulations of compartment CE (see Table 1) have considerably higher precision than cor-
responding estimates of maximum values and b-parameters (details see Additional file 1:
Figure S4).
Validation of model
Most of the scenarios for which we have data were not used for parameter fitting but
for validation purposes. This requires that necessary parameters for the simulation of a
particular scenario were either determined by previous fitting steps or can be taken from
the single lineage models.
Throughout, scenarios with growth-factor administration in healthy volunteers were
used to validate our hybrid model (data sets 1–46, 61–84 in table A.10 of the Additional
file 1), since the majority of required parameters were determined in the framework of
the single lineage models.
The situation for scenarios including chemotherapy is more complicated: At least one
scenario must be fitted to determine the toxicity parameters of an unknown drug combi-
nation, but often, toxicity parameters determined in the single lineage models performed
also fine for the hybrid model. This applied for the scenarios 85–96 of table A.10 com-
prising literature data of Carboplatin and Paclitaxel or Doxorubicin and Docetaxel with
injections of Filgrastim or Pegfilgrastim or CHOP-like therapies (therapies which are
similar to the CHOP combination therapy consisting of the drugs Cyclophosphamide,
Doxorubicin, Vincristin and Prednisone). Additionally, the data of high CHOEP 14 (data
set 57), CHOEP 14 and CHOP 14 (data sets 53 and 55, subgroup of young patients) were
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also not included into the fitting procedure but used for validation. For the majority of
chemotherapy scenarios, only WBC or ANC data are available. Hence, validation of the
granulopoiesis sub-model relies on a considerably larger data base.
Results
Model behaviour
After calibration, we study the qualitative behaviour of the model and compare it later
with the results of the single lineage models. In our hybrid model, we have additional
feedbacks due to the G-CSF effect on CE cells, the indirect effect of erythropoietic bone
marrow cells on granulopoiesis and vice versa via regulation of the proliferative frac-
tions of S, CE, BE and CG as well as the regulation of stem cell self-renewal probability.
Feedbacks are negative throughout resulting in more or less damped oscillations of com-
partment sizes after disturbance of the system. This behaviour is robust against changes of
model parameters except for those involved in stem cell feedback: If proliferative fraction
and stem-cell self-renewal are allowed to respond more intensively to changes of bone
marrow contents, disturbances of the system result in stable oscillations, a phenomenon
which was formerly used to explain cyclic neutropenia in dogs ([61,62], see Figure S3 in
the Additional file 1).
We study model dynamics after single perturbation and compare them with the results
of the single lineage models (see section ‘Comparison of the single lineagemodels and the
hybrid model’). At first, we simulate a single i.v. injection of 150 IU/kg EPO Alfa at t=0
(see Figure 3): The MEB compartment of the hybrid model expands quickly, followed by
a peak in reticulocytes. Since initially, amplification in BE and CE is stimulated by EPO,
Figure 3 Model behaviour after single injection of EPO.We present cell counts normalised to steady
state values after i.v. injection of 150 IU/kg EPO Alfa. After damped oscillations of compartment sizes the
system converges to equilibrium state.
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these compartments also show increasing cell counts. The compartment S also increases
initially, caused by the up-regulation of the self-renewal probability due to increased
bone marrow cell counts. In contrast, the compartment PEB is depleted by the short-
ened maturation time and thereby increased efflux into the compartment MEB. After
a minimal decrease in the number of CG and PGB the granulopoietic cells follow the
oscillation in S. Overall, damped oscillations of the compartment sizes can be observed.
Next, we simulated a single s.c. injection of Filgrastim at t=0 (see Figure 4 left panels):
ANC grows fast caused by the increased release of mature granulocytes from bone mar-
row to circulation. Thereafter, the GRA compartment is reduced rapidly caused by the
fast degradation of Filgrastim and the short half life of granulocytes. Since the prolifera-
tion in PGB is increased by G-CSF, this compartment also grows initially. The number of
stem cells increases (similarly to EPO application) due to up-regulation of self-renewal.
The number of erythropoietic cells is decreased due to the G-CSF effect on CE. Again,
all cell counts show damped oscillations, which is typical for short-term disturbances of
the system. After Pegfilgrastim administration (see Figure 4 right panels), the cell num-
bers react similarly, but increments and reductions of cell counts remain for a longer time
frame than after Filgrastim application. In contrast to Filgrastim application, no oscil-
lations occur after Pegfilgastim application. The reason for this behaviour is the longer
half-life of Pegfilgrastim compared to Filgrastim. Pegfilgrastim applications result in
prolonged stimulations of the bonemarrow, and with it, an expanded stem cell pool which
is only gradually reduced after elimination of Pegfilgrastim.
Figure 4 Model behaviour after single injection of G-CSF.Model behaviour after perturbation with
respect to steady state values. We present cell counts normalised to steady state values after a single s.c.
injection of 300 μg Filgrastim (left) or 300 μg Pegfilgrastim (right). A single Filgrastim injection results in
damped oscillations of compartment sizes, which was not observed for Pegfilgrastim.
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Nowwe study the effects of continuous stimulation with EPO and G-CSF (see Figure 5).
For this purpose, we keep EPO and G-CSF serum concentrations constant at higher val-
ues. This is achieved by constant influxes into these compartments. EPO stimulation
results in rapidly increasing numbers of MEB and RET. After oscillation, a new steady
state of BE, CE, MEB and RET on a higher level compared to the unperturbed steady
state is achieved. In contrast, the cell number in PEB reaches a slightly lower equilib-
rium after an initial strong decline. After an initial peak the stem cells stabilise on a
slightly lower level. The numbers of CG, PGB, MGB and ANC decline to a lower steady
state.
A continous administration of G-CSF results in an increased equilibrium of PGB,MGB,
ANC and S. Compartments CG, BE, CE, PEB, MEB, RET and ERY stabilise on lower
levels.
Finally, we want to study the system behaviour after a single CHOP chemotherapy
administration at t = 0. Figure 6 illustrates the reaction of the system to this damaging
effect. After an initial growth of the numbers of CE and PEB, damped oscillations of both
lineages appear over a longer time period. The numbers of BE, MEB and RET show a
strong decline after chemotherapy administration. Later, they show damped oscillations
as well while they slowly approach their normal values. Erythrocytes are slightly dimin-
ished after chemotherapy and later their number grows slowly without oscillations. The
compartments S, CG, PGB, MGB and ANC were strongly depleted after chemotherapy
application. Later their numbers oscillate and they slowly converge to their normal values.
Figure 5 Model behaviour during continuous stimulation with EPO or G-CSF. Left: EPO, right: Filgrastim.
New steady states are reached after a certain time.
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Figure 6 Model behaviour after a single chemotherapy administration.We present cell counts
normalised to steady state values after a single administration of CHOP chemotherapy. Except for
erythrocytes, all lineages show damped oscillations over a longer time period.
Comparison of the single lineage models and the hybrid model
In this section, we compare simulation results after perturbations of the hybrid model
with corresponding results of the single lineage models. As in the previous sections,
we simulate single injections of EPO, Filgrastim, Pegfilgrastim and CHOP chemother-
apy (see Figure 7) respectively. Newly implemented interactions between erythropoiesis
and granulopoiesis in the hybrid model resulted in some differences (for further details,
see section “Model comparison” in A.9 of the Additional file 1). Generally, in the hybrid
model, stem cell oscillations are less damped than in the single lineage models, especially
after chemotherapy (CHOP). Interestingly, despite this observation, the simulation results
for HB and WBC are comparable between the hybrid and the single cell lineage models,
i.e. the lack of damping in S is compensated at later cell stages. Nevertheless, we predict
continued oscillations of mature blood cells after chemotherapy, an issue which could be
verified in patients.
Chemotherapy scenarios
Chemotherapy toxicity parameters were re-estimated by fitting the predictions of the
model to our data sets (see tables of chemotherapy parameters in the Additional file 1 and
section ‘Estimation of parameters’).
In Figures 8, 9 and 10 we present a selection of chemotherapy scenarios for which
WBC and HB data are available, i.e. which could not completely be described by our for-
mer single lineage models. Scenarios comprise CHOP chemotherapy for the treatment of
aggressive non-Hodgkin’s lymphoma disease with different dosing and timing schedules
of Filgrastim (Figure 8) or Pegfilgrastim (Figure 9) and breast cancer therapies supported
by Filgrastim and EPO (Figure 10). Note that these are multi-cycle therapies in which
a drug or drug combination is applied multiple times, usually with 14 days or 21 days
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Figure 7 Comparison of dynamics after CHOP chemotherapy. Comparison of the behaviour of the
combined and the single lineage models after perturbation with CHOP chemotherapy. We present stem cell
dynamics, CE, HB and WBC normalised to steady state values.
intervals (see figure legends and table A.10 in the Additional file 1 for details). We
obtained a good agreement of model and data for all scenarios. Simulation results of the
single cell lineage models and the combined model are comparable throughout. In the
Additional file 1 we present the results of further chemotherapy scenarios (Figures S27,
S33–S40, compare with table A.10).
Validation
Scenarios not included into the fitting procedure are suitable for validation of the hybrid
model. For example, in [64] time series data of reticulocytes, WBC, HB and HK after mul-
tiple injections of 5000 IU EPO beta into healthy volunteers are presented. This scenario
was not included into the fitting procedure of both single lineage models as well as the
hybrid model. For the latter one, we observed a good fit of the data of both cell lineages
over a longer time period of 15 weeks (see Figure 11).
Results of the other validation scenarios can be found in the Additional file 1. We
observed a reasonable fit for all of these scenarios demonstrating the validity of our
model.
Model predictions
BEACOPP escalated is an intense chemotherapy for the treatment of Hodgkin’s lym-
phoma resulting in high degrees of toxicity affecting all haematopoietic lineages [49,65].
G-CSF but not EPO support is mandatory. In consequence, anaemia due to cumulative
toxicity to erythropoiesis is common at later cycles of the therapy. Here we simulate the
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Figure 8 Model simulations of different CHOP chemotherapies with or without Filgrastim support.
First row: Six cycles of CHOP with cycle duration of 21 days without Filgrastim, second row: Six cycles of CHOP
with cycle duration of 14 days with Filgrastim at day 4–13 at each therapy cycle, third row: Eight cycles of
CHOP with cycle duration of 14 days with Filgrastim at day 6–12 at each therapy cycle. We present time series
of HB and WBC simulated with our combined model (black solid line) and compare it with corresponding
simulation results of the single lineage models (grey solid line). We also compare model results with our
clinical data (median: circles, first and third quartile: grey dashed line) taken from the trials published in [45,63].
Figure 9 Model simulations of six cycles of CHOP chemotherapy with cycle duration of 14 days and
different Pegfilgrastim support.We present time series of HB and WBC simulated with our combined
model (black solid line). We compare model results with our clinical data (median: circles, first and third
quartile: grey dashed line) taken from clinical trials [5].
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Figure 10 Hybrid model simulations after chemotherapy, Filgrastim or EPO.We present results of
different breast cancer therapies. First row: four cycles of the drug combination epirubicine +
cyclophosphamide followed by four cycles of paclitaxel with cycle duration of 21 days without G-CSF, second
row: three single drug cycles of epirubicine, paclitaxel, cyclophosphamide applied consecutively with cycle
duration of 14 days with Filgrastim on cycle days 3–10, third row: The same therapy as described in second
row but with additional EPO Alfa. We show HB and WBC values of simulation (black line), medians (circle),
25th and 75th percentiles (grey dashed line) of patients data. While raw data are available for the first two
scenarios, data of the third scenario are taken from [51].
effect of concomitant G-CSF and EPO applications during the course of the therapy. We
simulate the application of eight cycles BEACOPP-21 escalated chemotherapy with Fil-
grastim on days 8–15 with or without weekly application of 300 IU/kg Darbepoetin (see
Figure 12, left). WhileWBC dynamics are roughly the same, the decrease of HB is delayed
by EPO possibly resulting in better quality of life of patients.
We also analysed the effect of weekly injections of 300 IU/kg Darbepoetin during eight
cycles of CHOP-14 chemotherapy in elderly patients. Here, Filgrastim was applied on
days 6–12 during each cycle of therapy.While dynamics ofWBC are similar, HB stabilises
at higher values during treatment with Darbepoetin.
Discussion
Conventional cytotoxic chemotherapy plays a major role in cancer therapy. Development
of intensified regimen improved the outcome of several diseases [45,46,49,66,67] but is
limited by toxic side effects. A major dose-limiting side effect is general haematotoxicity
which is routinely treated with growth factors EPO and G-CSF. Different pharmaceu-
tical derivatives of these factors are available, which differ greatly in pharmacokinetic
and -dynamic properties. Furthermore, outcome of growth factor treatment depends on
many factors such as chemotherapy drugs used, drug doses, growth-factor derivatives and
individual risk factors [68,69]. Due to this variety of variable therapy parameters, iden-
tification of optimal growth-factor schedules cannot be performed solely on the basis
of clinical trials. We showed in the past that mathematical models of haematopoiesis
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under chemotherapy can facilitate the development of optimised and individualised
growth-factor schedules [6].
Efforts to model haematopoiesis under chemotherapy and growth-factor applications
are considerable [2,4,11-13,16,23,31,32,70-84]. All these attempts are based on mech-
anistic or semi-mechanistic parameterical models. In view of the complexity of the
haematopoietic system, it might be worthwhile to consider model-free forecasts of
haematopoietic outcomes (see discussion in [85,86]). However, to our knowledge, such an
approach has never been proposed.
There are only a few attempts to develop multilineage models or hybrids of exist-
ing model: In [87] a compartmental model of granulopoiesis and thrombopoiesis
including G-CSF and high dose chemotherapy application is proposed. Feedback mech-
anisms from thrombopoietic, granulopoietic and stem cells on stem cells and an
interaction between the G-CSF compartment and the white blood cells are included.
Erythropoesis was not considered. A stochastic multilineage model only considering
haematopoietic stem cells and progenitor cells based on the idea of lineage com-
mitment can be found in [42]. In [88] an ordinary differential equations model of
granulopoiesis under chemotherapy and Filgrastim injections was combined with a
model of stem cell plasticity. G-CSF and chemotherapy effects are modelled but ery-
thropoiesis was not included. In the recent version of our erythropoeisis model, we
combined a cell kinetic model with EPO injection models, with an EPO pharma-
cokinetic model and with a chemotherapy model developed for granulopoiesis. But
granulopoiesis was not considered. In [89,90] several earlier models of haematopoi-
etic stem stell dynamics and models for the regulation of neutrophils, platelets and
erythrocytes were combined to a model of the regulation of the hematopoietic
Figure 11 Example validation scenario. Data of Lundby et al. [64] after multiple injections of EPO Beta.
Time series of WBC, HB, Reticulocytes and HK are presented. Solid black curve represents simulation results.
Circles and grey line represent means and standard deviations respectively [64].
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Figure 12 Prediction scenarios.We present predictions regarding BEACOPP-escalated and CHOP 14
(elderly) supported by Filgrastim and weekly Darbepoetin starting on day 0. Simulation results of WBC and
HB are shown as black curve. Grey curves show predictions of dynamics without additional Darbepoetin
applications. Median of data is represented by circles, and grey hatched line describe first and third quartile of
the data [49,63].
system describing periodic chronic myelogenous leukemia and cyclical neutrope-
nia taking G-CSF effects into account. Chemotherapy was not considered in these
models.
Here, we propose a comprehensive combinedmodel of human erythropoiesis and gran-
ulopoiesis under chemotherapy, G-CSF and EPO applications for the first time. For this
purpose, we combined a former cell kinetic model of erythropoiesis under chemotherapy
and EPO applications developed by our group [10-13,16] with a cell kinetic model of gran-
ulopoiesis under chemotherapy and G-CSF applications [3,4,12,23]. These models were
chosen for their clinically relevant applications and parameter settings established on the
basis of large clinical datasets. Models are based on an ordinary differential equations
system describing major cell stages in bone marrow and blood as well as dynamics of
key cytokines. Rather than constructing a combined model from scratch we rely on these
establishedmodeling works and adopted their assumptions, equations and parameter set-
tings as far as possible. Therefore, this approach can be considered as a second level of
modeling by the combination of establishedmodels in order to buildmore comprehensive
ones.
Accordingly, only a few additional assumptions and only a few new parameters were
introduced in order to combine the model. The most challenging issue was to com-
bine the models at stem cell level since regulation of stem cells dynamics depend on
mature cell stages which was modelled differently in our single lineage models. This
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was solved by substituting the stem cell regulation by a model originally developed
by Loeffler and Wichmann [12]. The model includes elements of lineage competition
with respect to stem cell differentiation. Evidences of interactions between cell lineages
regarding stem cell committment are summarised in [7]. Since model behaviour depends
heavily on stem cell dynamics, it was by far not clear whether this approach would be
successful. Indeed, this adaptation later required re-estimations of toxicity parameters
of chemotherapy since stem cell toxicities are highly sensitive with respect to model
outcome.
A second assumption was made with respect to suppression of erythropoiesis by G-
CSF: Previous experiments have shown, that G-CSF administration leads to a reduction of
CFU-E in the femur of mice [8,91-93]. Bungart et al. measured a decline of bone marrow
CFU-E in mice to about % of the control value [91]. Bensinger et al. detected a greater
decrease of hematocrit values in human blood donors receiving rhG-CSF than in donors
without G-CSF [9]. However, the groups with or without G-CSF were not comparable. In
view of these observations, we assumed that G-CSF decreases proliferation and prolonges
transition time in CE [43]. However, our model simulations show that assuming a delay of
the transition time in dependance on G-CSF dose and derivative is sufficient to describe
the phenomena observed in human studies. Generally, suppression of erythropoiesis by
G-CSF becomes apparent only under high serum levels of G-CSF over a longer time scale
such as after Pegfilgrastim injections.
In summary, the major achievement of our present modelling efforts is that we suc-
cessfully combined our single lineage models of erythropoiesis and granulopoiesis under
chemotherapy by introducing a common stem cell model and an interaction of the lin-
eages mediated by G-CSF. The model is mechanistic in the sense that it directly describes
amplification and maturation processes of cell stages, relevant cell fluxes and PK/PD of
EPO and G-CSF derivatives. However, we also have to acknowledge that our model is
semi-mechanistic with respect to stem cell feedback and chemotherapy action which
both are only phenomenologically described. This constitutes possible starting points for
future model improvements.
While we rely on the parameter estimates of the single lineage models in general,
newly introduced parameters based on assumptions necessary to combine the model
were determined by fitting the predictions of the model to clinical data. Additionally, as
mentioned earlier, it was also necessary to re-estimate toxicity parameters of chemother-
apeutic drugs due to the changes required for stem cell modelling. It was our objective
to construct a model predicting medians of patients, i.e. patients heterogeneity was not
considered so far. We considered virtually all available time series data of mature blood
parameters and cytokine levels after application of G-CSF, EPO, chemotherapy and com-
binations of it in order to parametrise the model or to validate its results. Data were
retrieved either from the literature or from our own clinical study groups for which we
have access to raw data of patients. This results in more than 100 scenarios comprising 15
different chemotherapeutic regimens.
In order to compare the results of our hybrid model with those of our single lineage
models, we performed a number of qualitative simulations, namely single applications
of G-CSF, EPO or chemotherapy. We observed some differences with respect to the
dynamics of stem cells and earlier bone marrow compartments. In general, correspond-
ing oscillations in the hybrid model are stronger and less damped compared to the single
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lineage models. However, this effect is only predicted for earlier cell stages for which no
data are available. Due to additional regulations by G-CSF, the dynamics at later cell stages
are almost identical to those of the former version of the model showing less pronounced
oscillations at stem cell level. A similar observation was made by combining a two-
dimensional difference equation model of stem cell regulation with our granulopoiesis
model [88]. Thus, one can conclude that dynamics of blood cells are less informative
regarding stem cell dynamics, i.e. appropriateness of different stem cell models can hardly
be decided on the basis of available clinical data.
With the hybrid model we simulated more than 100 scenarios including growth fac-
tor applications in healthy volunteers, chemotherapy without growth factor application
and chemotherapy with supportive G-CSF, EPO or both. Although there is a consider-
able inhomogeneity between patient groups considered (different age groups, diseases,
distributions of risk factors) a good agreement between model simulation and data was
achieved for almost all scenarios using a single parameter set (except for different toxi-
city parameters used for young and elderly patients). However, one has to acknowledge
that the dynamics of white blood cells during chemotherapy is richer, and thus, more
informative regarding appropriateness of model behaviour than the dynamics of the
erythropoietic lineage. Reticulocyte data are scarcely available while erythrocytes, haema-
tocrit or haemoglobin show more or less a constant decline in the time course of the
therapy.
The majority of available data sets were used for model validation rather than parame-
ter estimation. This especially applies for data after growth factor application into healthy
volunteers for which no additional toxicity parameters are required. Additionally, a num-
ber of chemotherapy scenarios for which toxicity parameters were available from earlier
modelling steps, were also used for model validation. The good agreement of model and
data for almost all validation scenarios shows that the model covers a wide range of
scenarios. Unfortunately, often data of only one of the lineages are available from the lit-
erature. Data received from our clinical trials are most detailed resulting in close meshed
time series at a daily scale supported by dozens of single measurements. However, only
data of leukocyte and haemoglobin are available to support our modelling. It would
greatly benefit frommore detailed blood parametersmeasured in parallel such as erythro-
cytes, hematocrit, hemoglobin, reticulocytes, iron status, and lymphocytes, granulocytes
rather than leukocytes.
Finally, we demonstrated how the model could be used to make clinically relevant
predictions regarding the outcome of different growth-factor schedules after chemother-
apy. This requires that the toxcity parameters of the therapy are available from previous
fitting steps. Then, the model can be used to simulate and compare alternative growth-
factor schedules. We predict for example that both, patients treated with CHOP 14 or
BEACOPP escalated therapy, would benefit from weekly Darbepoetin treatment without
reducing the effectiveness of concomittant G-CSF treatment. Clinical trials are required
to validate these model predictions.
However, we have to acknowledge that the present model only allows median pre-
dictions while critical time-courses are clinically more relevant and therapy-limiting.
Although this aspect is not yet covered, there is a clear perspective towards modelling
individual data either by fitting parameter sets for patient risk groups or by assuming dis-
tributions of model parameters. Accordingly, we plan to extend our model in the near
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future and apply it in order to support improvement and individualisation of growth
factor therapies.
Conclusions
We successfully combined established bio-mathematical models of granulopiesis and
erythropoiesis under chemotherapy and growth-factor applications by introducing a
common stem cell compartment and lineage interactions. The model explains data of
about 100 clinical scenarios including 15 different chemotherapies and six growth-factor
derivatives. We demonstrated how the model can be used to make clinically relevant
predictions regarding combined G-CSF and EPO treatment during chemotherapy.
Additional file
Additional file 1: A combinedmodel of human erythropoiesis and granulopoiesis under growth factor and
chemotherapy treatment: Supplement material. The file ERYGRAsupp.pdf contains major model variables and
mechanisms of the cell kinetic model. We provide all equations and parameters necessary to run the model.
Additional simulation results are also included.
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